Literature DB >> 8640668

Proliferation index and vascular density of giant cell tumors of bone: are they prognostic markers?

M A Sulh1, M A Greco, T Jiang, S B Goswami, D Present, G Steiner.   

Abstract

BACKGROUND: The proliferation index (PI) and vascular density (VD) in giant cell tumors (GCT) of bone were studied to assess then value as prognostic markers.
METHODS: Formalin fixed, paraffin embedded tissue from 7 nonrecurrent (NR-GCT) and 13 recurrent (R-GCT) tumors were stained with MIB-1, a monoclonal antibody against Ki-67 (nuclear proliferation antigen), and QBEND-10, a monoclonal antibody against CD34 (endothelial antigen). A minimum of ten fields/case were analyzed on the SAMBA 4000 Image Analyzer. Only mononuclear cell nuclei were analyzed for MIB-1 staining.
RESULTS: Mean values +/- 1 Standard deviation (SD) for PI (stained nuclear area/total nuclear area) were: NR-GCT, 10.98 +/- 3.70; R-GCT (initial presentation), 8.94 +/- 3.57; and R-GCT (first recurrence), 9.25 +/- 3.52. In addition, the mean PI +/- 1 SD for mononuclear round-ovoid cells was 8.71 +/- 3.47 and was 9.16 +/- 10 for mononuclear spindle cells. The mean values +/- 1 SD for VD (stained area/total area of structures) were: NR-GCT, 10.61 +/- 6.37; R-GCT (initial curettage), 9.40 +/- 4.94; and R-GCT, (first recurrence), 12.56 +/- 5.88. Comparing the means for PI and VD for both groups of tumors using Student's t test showed no statistically significant differences (P = 0.34). In one case of histologically benign GCT that metastasized to the lungs, the PI of the metastatic tissue was not significantly different from the primary tumor.
CONCLUSIONS: This study presents evidence that the degree of tumor cell proliferation and vascularity are not useful parameters to predict the recurrence of GCT of bone and that there are no significant differences between the PI of mononuclear round-ovoid cells and mononuclear spindle cells.

Entities:  

Mesh:

Year:  1996        PMID: 8640668     DOI: 10.1002/(SICI)1097-0142(19960515)77:10<2044::AID-CNCR12>3.0.CO;2-V

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  7 in total

1.  Morphological and immunophenotypic features of primary and metastatic giant cell tumour of bone.

Authors:  M Alberghini; K Kliskey; T Krenacs; P Picci; L Kindblom; R Forsyth; N A Athanasou
Journal:  Virchows Arch       Date:  2009-12-15       Impact factor: 4.064

2.  Histopathological, immunohistochemical, and image analytic parameters characterizing the stromal component in primary and recurrent giant cell tumor of bone.

Authors:  Charu Chandra Saxena; Rajni Safaya; Neha Kawatra Madan; Shah Alam Khan; Venkateswaran K Iyer
Journal:  J Clin Orthop Trauma       Date:  2015-10-26

3.  p53 mutations may be involved in malignant transformation of giant cell tumor of bone through interaction with GPX1.

Authors:  Taketo Okubo; Tsuyoshi Saito; Hiroyuki Mitomi; Tatsuya Takagi; Tomoaki Torigoe; Yoshiyuki Suehara; Kazuo Kaneko; Takashi Yao
Journal:  Virchows Arch       Date:  2013-06-08       Impact factor: 4.064

Review 4.  Vasculogenic mimicry and tumor angiogenesis.

Authors:  R Folberg; M J Hendrix; A J Maniotis
Journal:  Am J Pathol       Date:  2000-02       Impact factor: 4.307

5.  Metachronous multicentric giant-cell tumor of the bone in the lower limb. Case report and Ki-67 immunohistochemistry study.

Authors:  Marc-Antoine Rousseau; Adriana Handra-Luca; Jean-Yves Lazennec; Yves Catonné; Gérard Saillant
Journal:  Virchows Arch       Date:  2004-05-11       Impact factor: 4.064

6.  Tartrate-Resistant Acid Phosphatase 5b is a Useful Serum Marker for Diagnosis and Recurrence Detection of Giant Cell Tumor of Bone.

Authors:  Tetsuya Shinozaki; Kenichi Saito; Tsutomu Kobayashi; Takashi Yanagawa; Kenji Takagishi
Journal:  Open Orthop J       Date:  2012-09-03

7.  Giant cell tumour and central giant cell reparative granuloma of the skull: do these represent ends of a spectrum? A case report and literature review.

Authors:  Sonia Saw; Nick Thomas; Michael J Gleeson; István Bódi; Steve Connor; Tibor Hortobágyi
Journal:  Pathol Oncol Res       Date:  2008-11-15       Impact factor: 3.201

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.